Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Molecular Medicine Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 1791-2997 Online ISSN: 1791-3004
Journal Cover
September-2016 Volume 14 Issue 3

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
September-2016 Volume 14 Issue 3

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Nitidine chloride inhibits proliferation, induces apoptosis via the Akt pathway and exhibits a synergistic effect with doxorubicin in ovarian cancer cells

  • Authors:
    • Feng Ding
    • Tianfeng Liu
    • Nina Yu
    • Shihong Li
    • Xiaofei Zhang
    • Guanghong Zheng
    • Chunming Lv
    • Kai Mou
    • Jia Xu
    • Bo Li
    • Surong Wang
    • Haibo Song
  • View Affiliations / Copyright

    Affiliations: Department of Gynecology and Obsterics, Linyi People's Hospital, Linyi, Shandong 276000, P.R. China, Prenatal Diagnosis Center, Zibo Maternal and Child Health Hospital, Zibo, Shandong 255000, P.R. China, Department of Cardiology, Central Hospital of Zibo, Zibo, Shandong 255036, P.R. China
  • Pages: 2853-2859
    |
    Published online on: July 29, 2016
       https://doi.org/10.3892/mmr.2016.5577
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Nitidine chloride (NC) exhibits anti-tumor properties in various types of tumor. However, to the best of our knowledge there is no previous evidence of NC involvement in the apoptosis or proliferation of ovarian cancer cells and the underlying molecular mechanisms. The present study aimed to investigate the influence of NC on the viability and apoptosis of ovarian cancer cells and the synergistic effect NC and doxorubicin (DOX) may have on ovarian cancer cells. The viability and proliferation of ovarian cancer cells were examined using a methyl thiazolyl tetrazolium assay and 3H-thymidine incorporation assay. The apoptotic rate of ovarian cancer cells was detected by flow cytometry. The expression of apoptosis‑associated proteins and Akt serine/threonine kinase 1 (Akt) were determined by western blot analysis following NC treatment. The inhibitory effect of NC on the proliferation of ovarian cancer cells was demonstrated in a time and dose‑dependent manner. The pro-apoptotic effect of NC on ovarian cancer cells was also observed. It was determined that NC significantly downregulated the protein expression levels of B‑cell CLL/lymphoma 2 (Bcl-2) and upregulated the expression of Bcl‑2‑associated X protein, p53, caspase‑3 and ‑9. NC suppressed Akt phosphorylation. Additionally, the present study demonstrated that the effect of NC on the proliferation and apoptosis of ovarian cancer cells was Akt‑dependent by using the phosphatidylinositol-4,5-bisphosphate 3-kinase/Akt signaling pathway inhibitor, LY294002. NC exhibited a synergistic inhibitory effect on the viability of ovarian cancer cells when combined with DOX. The current study demonstrated that NC inhibited the proliferation and induced the apoptosis of ovarian cancer cells via the Akt signaling pathway and highlighted its potential clinical application for the treatment of ovarian cancer.

Introduction

Ovarian cancer is a lethal gynecological malignancy and the fifth leading cause of cancer-associated mortality worldwide. In 2013, there were >2 million novel cases of ovarian cancer and 1 million mortalities worldwide (1–3). Chemotherapy following surgical resection is the current primary treatment for localized ovarian cancer. Progress has been made in early diagnosis of patients; however, treatment options for the majority of patients with advanced stage ovarian cancer remain limited. Particularly, resistance to chemotherapeutical drugs often leads to poor prognosis (4–6). Therefore, it is important to investigate the potential molecular mechanisms underlying the pathogenesis of ovarian cancer, and to identify novel therapeutic agents and combination regimens in order to improve the treatment and prognosis of patients with ovarian cancer.

Nitidine chloride (NC) (Fig. 1A) is isolated from the root of Zanthoxylum nitidum (Roxb). Numerous pharmacological properties of NC have been previously reported, including anti-oxidant, anti-inflammatory, anti-fungal, analgesic and anti-human immunodeficiency virus functions (7,8). Previous studies have determined that NC exhibits anti-tumor activity in several types of cancer. Additionally, NC inhibits cell proliferation and induces apoptosis in renal cancer, gastric cancer, breast cancer and hepatocellular carcinoma (9–12). NC was also capable of suppressing the invasion and metastasis of renal cancer via the Akt serine/threonine kinase 1 (Akt) pathway, and breast cancer by inhibiting the SRC proto-oncogene, non-receptor tyrosine kinase/focal adhesion kinase-associated signaling pathway (13,14). However, to the best of our knowledge, no evidence has previously reported whether NC exerts any effect on ovarian cancer proliferation, apoptosis and its underlying mechanisms. NC may be successful in treating ovarian cancer; however, the synergistic effect of NC and other therapeutic agents requires further investigation.

Figure 1

NC inhibited the proliferation of A2780 ovarian cancer cells. (A) Chemical structure of NC. (B) NC treatment for different time periods (24, 48 and 72 h) and different concentration gradients (0, 2.5, 5, 10, 20 and 50 µM), methyl thiazolyl tetrazolium assay was used to determine the viability of A2780 cells. (C) Following 40 h treatment with NC at different concentrations (0, 2.5, 5, 10 and 20 µM), 3H-thymidine incorporation assay was used to detect the proliferation of A2780 cells. *P<0.05, #P<0.01 vs. control group. Data are presented as the mean ± standard deviation of three independent experiments. NC, nitidine chloride.

The present study investigated the effects of NC on ovarian cancer cell proliferation and apoptosis. It was also determined that the Akt pathway is important for NC-induced apoptosis. Additionally, the synergistic effect of NC with doxorubicin (DOX) on ovarian cancer cells was evaluated.

Materials and methods

Cell lines and reagents

The A2780 human ovarian cancer cell line was purchased from the American Type Culture Collection (Manassas, VA, USA) and cultured in RPMI-1640 (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% fetal bovine serum (FBS; Invitrogen; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin, and 100 µg/ml streptomycin in 5% CO2 at 37°C. Rabbit anti-Akt (cat. no. 4685), phosphorylated-Akt (cat. no. 4058), B-cell CLL/lymphoma 2 (Bcl-2; cat. no. 2870), Bcl-2-associated X protein (Bax; cat. no. 502), p53 (cat. no. 2527), caspase-3 (cat. no. 9665) and -9 (cat. no. 9502) antibodies were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). NC was purchased from Tauto Biotech Co., Ltd. (Shanghai, China) and dissolved in dimethyl sulfoxide (DMSO). LY294002, a selective phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) Akt inhibitor, was purchased from Sigma-Aldrich (St. Louis, MO, USA). Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) apoptosis detection kit was purchased from BD Biosciences (Franklin Lakes, NJ, USA).

Methyl thiazolyl tetrazolium (MTT) assay of cell viability and proliferation

Cell viability and proliferation were detected by using MTT assay. A2780 cells in 100 µl RPMI-1640 were seeded at a density of 5.0×103 cells/well in 96-well plates. Following treatment with NC (0, 2.5, 5, 10, 20 or 50 µM) and/or DOX (0, 0.25, 0.5, 1, 2, 5 µM; Aladdin Reagents Co., Ltd., Shanghai, China) for different time-points (24, 48 or 72 h), 20 µl MTT (5 mg/ml) was added to each well. Subsequently, the cells were incubated for 4 h, then 100 µl DMSO was added to each well for another 15 min. Finally, the absorbance values were detected using a microplate luminometer (Bio-Rad Laboratories, Inc., Hercules, CA, USA) at 490 nm.

3H-thymidine incorporation assay

A2780 cells were cultured in RPMI-1640 with 10% FBS at 50% confluence. Next, the A2780 cells were cultured in serum-free RPMI-1640 for 24 h and treated with NC at different concentrations (0, 2.5, 5, 10, 20 µM) for 40 h. 3H-thymidine (final concentration 1 uCi/ml) was added to the media during the last 24 h of culturing. The cells were then washed with ice-cold phosphate-buffered saline (PBS), and precipitated with ice-cold 5% trichloroacetic acid (TCA; Sigma-Aldrich) for 4 h. The cells were washed with ice-cold 5% TCA twice, followed by washed with ice-cold PBS. Subsequently, the cells were lysed using 200 µl 0.5 M NaOH for 30 min at 37°C. DNA synthesis was determined by 3H-thymidine uptake using a liquid scintillation counter (LS-6500; Beckman Coulter, Inc., Brea, CA, USA).

Western blot analysis

Total cell protein concentrations were detected by using the Pierce bicinchoninic acid protein assay kit (Thermo Fisher Scientific, Inc.). Equal quantity of protein from cell lysates (10 µg) were loaded on 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels. Following electrophoresis, proteins were transferred to polyvinylidene fluoride membranes (EMD Millipore, Billerica, MA, USA), blocked with 5% fat-free milk at room temperature for 1 h, and incubated with the aforementioned primary antibodies overnight at 4°C. The membranes were subsequently washed with Tris-buffered saline Tween-20 and incubated with horseradish peroxidase-conjugated goat anti-rabbit secondary antibodies (cat. no. ZDR-5306; OriGene Technologies, Inc., Shanghai, China) for 1 h at room temperature. Immune complexes were detected with enhanced chemiluminescence reagents (EMD Millipore), and the blots were quantified by densitometric analysis using the AlphaImager IS 2200.

Apoptosis analysis by Annexin V/PI assay

Apoptosis of A2780 cells was detected by using the Annexin V-FITC/PI assay. A2780 cells were seeded into 6-well plates at a density of 1.0×106 cells/well. Following NC treatment (0, 10, 20 µM) for 24 h the A2780 cells were harvested, washed and resuspended in PBS. Apoptotic cells were determined using an Annexin V-FITC apoptosis detection kit according to the manufacturer's protocol. Briefly, the A2780 cells were washed and then incubated for 15 min at room temperature in the dark in 200 µl 1X binding buffer containing 5 µl Annexin V-FITC and 10 µl PI. The apoptotic rate was detected by the BD Accuri C6 flow cytometer (BD Biosciences) and processed using FlowJo software (version 7.0; Tree Star, Inc., Ashland, OR, USA).

Statistical analysis

Data are expressed as the mean ± standard deviation. All of the experiments were repeated at least three times. Comparisons among values for all groups were performed using a one-way analysis of variance with Dunnett's test for comparison of multiple groups. P<0.05 was considered to indicate a statistically significant difference.

Results

NC inhibits the proliferation of ovarian cancer cells

An MTT assay was performed to determine the effect of NC on ovarian cancer cell proliferation. As presented in Fig. 1B, NC significantly reduced the proliferation of ovarian cancer cells in a time- and dose-dependent manner compared with the control group (P<0.01). To verify the aforementioned findings, a 3H-thymidine incorporation assay was used to determine the importance of NC on the proliferation of ovarian cancer cells. As presented in Fig. 1C, NC (2.5, 5, 10 and 20 µM) significantly suppressed the proliferation of ovarian cancer cells compared with the control (P=0.038, P=0.0071, P=0.0062, P=0.0050, respectively). The 10 and 20 µM NC concentrations were selected for the subsequent experiments. These data suggested that NC effectively suppressed the proliferation of ovarian cancer cells.

NC induces apoptosis in ovarian cancer cells

To confirm that the inhibitory effect of NC on the proliferation of A2780 ovarian cancer cells was due to the direct effect on apoptosis, the A2780 cells were treated with NC (0, 10 and 20 µM) for 24 h. As presented in Fig. 2 it was determined that 10 and 20 µM NC significantly promoted the apoptosis of ovarian cancer cells compared with the control group (P=0.0035 and P=0.0010, respectively). The apoptotic rate of ovarian cancer cells increased from 2.3±1.3 (control) to 14.5±5.6 and 22.0±26.4% following treatment with 10 and 20 µM, respectively, for 24 h. These findings demonstrated the anti-tumor effect of NC on ovarian cancer cells.

Figure 2

NC induced dose-dependent apoptosis in A2780 ovarian cancer cells. (A) A2780 cells were treated with NC (0, 10 and 20 µM) for 24 h and double-stained with Annexin V and PI. Then the A2780 cells were analyzed with a flow cytometer. (B) The bar graph represents the mean ± standard deviation of three independent experiments. #P<0.01 vs. the control group. NC, nitidine chloride; PI, propidium iodide.

NC induces the apoptosis of ovarian cancer cells via altered expression levels of apoptosis-associated proteins

In order to determine the underlying mechanism of ovarian cancer cell apoptosis induced by NC, the protein expression levels of Bax, Bcl-2, p53, caspase-3 and -9 were determined. Western blot analysis demonstrated that, following treatment with NC (10 and 20 µM), the expression levels of pro-apoptotic protein Bax were significantly upregulated (P=0.0074 and P=0.0058, respectively; Fig. 3) and the expression levels of the anti-apoptotic protein, Bcl-2 were significantly downregulated compared with the control group (P=0.0062 and P=0.0044, respectively; Fig. 3). Simultaneously, the protein expression levels of p53 (10 µM NC, P=0.031; 20 µM NC, P=0.0040), caspase-3 (10 µM NC, P=0.0054; 20 µM NC, P=0.0057) and −9 (10 µM NC, P=0.0055; 20 µM NC, P=0.0054) were also significantly upregulated compared with the control group (Fig. 3).

Figure 3

NC reduced the expression of Bcl-2 and increased the expression of Bax, Bcl-2, p53, caspase-3 and -9 in A2780 ovarian cancer cells. (A) A2780 cells were treated with NC (0, 10 and 20 µM) for 24 h. The expression levels of Bax, Bcl-2, p53, cleaved caspase-3 and -9 in cell lysates were detected using western blot analysis. (B) Statistical analysis of the western blot results. *P<0.05, #P<0.01 vs. control group. Data are presented as the mean ± standard deviation from three independent experiments. NC, nitidine chloride; Bax, Bcl-2-associated X protein; Bcl-2, B-cell CLL/lymphoma 2.

NC inhibits Akt phosphorylation in ovarian cancer cells

The Akt signaling pathway is important for tumor progression. To determine the molecular mechanism involved in the effect of NC on the proliferation and apoptosis of ovarian cancer cells, the Akt signaling pathway was examined. As presented in Fig. 4A and B, Akt phosphorylation was significantly downregulated by treatment with NC (10 and 20 µM; P=0.0041 and P=0.0045, respectively) for 24 h, compared with the control group (P<0.01). This indicated that the Akt signaling pathway may be involved in the viability and apoptosis of ovarian cancer cells.

Figure 4

NC inhibited Akt phosphorylation and the pro-apoptotic effect on A2780 cells was Akt-dependent. (A) A2780 cells were treated with NC (0, 10 and 20 µM) for 24 h and the levels of p-Akt, Akt were analyzed by western blotting. (B) Statistical analysis of the western blotting results. #P<0.01 vs. control group. (C) A2780 cells were pretreated with the Akt inhibitor LY (50 µM) for 30 min followed by incubation with or without NC (20 µM) for 24 h. The expression levels of p-Akt, Akt, Bax, Bcl-2, caspase-3 and -9 were detected by western blotting with GAPDH as an internal control. (D) Statistical analysis of the western blotting results. *P<0.05, #P<0.01 vs. control group, §P<0.01 vs. NC-treated group. Data are presented as the mean ± standard deviation from three independent experiments. p-Akt, phosphorylated-AKT serine/threonine kinase 1; NC, nitidine chloride; Bax, Bcl-2-associated X protein; Bcl-2, B-cell CLL/lymphoma 2; LY, LY294002.

Suppression of the Akt signaling pathway enhanced the pro-apoptotic and anti-proliferative effect of NC on ovarian cancer cells

LY294002, a PI3K inhibitor, was used to stop Akt phosphorylation. As presented in Fig. 4C and D, the inhibition of Akt phosphorylation with LY294002 significantly enhanced the NC-induced downregulation of the Bcl-2 expression levels compared with NC treatment only (P=0.0061), whereas the expression levels of Bax, caspase-3 and -9 were significantly upregulated by LY294002 + NC treatment compared with 20 µM NC treatment alone (P=0.0033, P=0.0041 and P=0.0052). These findings indicated that NC-induced apoptosis may be PI3K/Akt-dependent. Furthermore, the effect of NC on the proliferation of ovarian cancer cells and the PI3K/Akt signaling pathway was determined using an MTT assay (Fig. 5A) and 3H-thymidine incorporation assay (Fig. 5B). As presented in Fig. 5A, the PI3K/Akt inhibitor LY294002, significantly enhanced the NC-induced suppression of the proliferation of ovarian cancer cells compared with the control and the NC-only treated group (P=0.0057, 24 h; P=0.0051, 48 h). As demonstrated in Fig. 5B, LY294002 enhanced 3H-thymidine incorporation compared with NC alone (P=0.0066). Therefore, blocking Akt activation may significantly enhance the NC-induced suppression of the proliferation of ovarian cancer cells.

Figure 5

NC inhibited the proliferation of A2780 cells. (A) A2780 cells were pretreated with LY (50 µM) for 30 min followed by incubation with or without NC (20 µM) for 24 and 48 h, cell viability was determined by methyl thiazolyl tetrazolium assay. (B) A2780 cells were pretreated by using LY (50 µM) for 30 min followed by incubation with or without NC (20 µM) for 40 h, then cell proliferation was determined by 3H-thymidine incorporation assay. Data are presented as the mean ± standard deviation from three independent experiments. #P<0.01 vs. control group, §P<0.01 vs. NC-treated group. NC, nitidine chloride; LY, LY294002.

NC exhibits a synergistic effect with DOX on limiting cell viability of ovarian cancer cells

A previous study on anti-tumor agents focused on limiting drug resistance of traditional chemotherapeutic agents by combining with novel anti-tumor drugs to achieve optimal curative effects (14). In order to investigate the synergistic effect of NC and DOX on A2780 ovarian cancer cells, the cells were treated with various doses of DOX (0, 0.25, 0.5, 1, 2, 5 µM) and NC (2 µM) for 48 and 72 h (Fig. 6A and B). The cell viability was examined by MTT assays. DOX alone or in combination with NC (2 µM) inhibited the viability of ovarian cancer cells in a time- and dose-dependent manner. Notably, the viability of A2780 cells was decreased from 84.2±11.2 to 43.5±7.1 (P=0.0063), and 45.7±6.8 to 31.8±5.3% (P=0.034), respectively, when treated with 0.25 and 0.5 µM DOX, in combination with NC (2 µM) at 48 h. For the 72 h treatment, the viability of A2780 cells decreased from 55.9±9.2 to 44.6±6.1% (P=0.0083) when treated with 0.25 µM DOX in combination with NC (2 µM). These findings indicated that the combination of DOX and NC exerted a synergistic inhibitory effect on the viability of the ovarian cancer cells.

Figure 6

Synergistic effect of NC and DOX on the viability of A2780 cells. Subsequent to treatment with DOX alone (0.25, 0.5, 1, 2, 5 µM) or in combination with NC (2 µM) for (A) 48 h and (B) 72h, A2780 cell proliferation was detected using an methyl thiazolyl tetrazolium assay. Data are presented as the mean ±standard deviation of three independent experiments. **P<0.01 vs. 0 μM controls; #P<0.05, ##P<0.01 vs. DOX-treated group. DOX, doxorubicin; NC, nitidine chloride.

Discussion

Uncontrolled proliferation and resistance to apoptosis of tumor cells is considered to contribute to mortality in patients with ovarian cancer (15,16). Conventional chemotherapeutic agents have limited long-term application due to their side effects. Therefore, understanding the molecular mechanisms of proliferation and apoptosis, and developing effective approaches to inhibit proliferation and induce apoptosis of cancer cells are the crucial for cancer research. Therefore, investigations of the therapeutic features of natural products in tumor therapy are frequently performed (17,18). As a bioactive phytochemical alkaloid extracted from Zanthoxylum nitidum (Roxb), NC exhibits multiple pharmacological effects on oxidation and inflammation (7,8). Previous studies have demonstrated the capacity of NC to induce apoptosis and inhibit of proliferation, migration and invasion in breast, renal, hepatocellular carcinoma and gastric cancer cells (9–14). However, the effect of NC on ovarian cancer apoptosis and proliferation had not been fully elucidated and the molecular mechanisms were unclear. To the best of our knowledge, the current study was the first to demonstrate that NC may effectively suppress the viability of ovarian cancer cells and induce their apoptosis. The mechanism of proliferation inhibition by NC was due to downregulation of the Akt signaling pathway. Therefore, a novel molecular mechanism that allows NC to exhibit the anti-tumor activity in ovarian cancer cells was identified.

Cell apoptosis is regulated by various factors, including Bcl-2 protein family members and caspases (19). The Bcl-2 protein family members, including the anti-apoptotic proteins (Bcl-2, Bcl-2-like 1, Bcl-2-like 2 and myeloid cell leukemia 1) and pro-apoptotic proteins [Bax and Bcl-2-associated agonist of cell death (Bad)] are important for apoptosis and act via caspases (19,20). Previous studies have determined that in the process of apoptosis, the release of cytochrome C was regulated by Bax mitochondria translocation and oligomerization, which in turn activated caspase-3 and -9 (21,22). Subsequently, cell apoptosis is triggered by the inhibition of Bcl-2 and Bax oligomerization. Thus, Bcl-2 was understood to stabilize the mitochondrial membrane by blocking internal calcium release into the cytoplasm (23,24). A previous study demonstrated that the tumor suppressor, p53, was associated with several Bcl-2 protein family members involved in cell apoptosis (25). Previous studies have determined that NC inhibited the proliferation of renal and breast cancer cells by inducing apoptosis, and regulating the expression levels of Bcl-2 and Bax (9,12). The present study demonstrated that NC inhibited the proliferation of ovarian cancer cells and induced their apoptosis in a time- and dose-dependent manner. The expression levels of apoptosis-associated proteins (Bax and Bcl-2) in ovarian cancer cells, treated with NC were also investigated. It was determined that NC altered the expression level ratio of Bax to Bcl-2. Additionally, caspase-3 and -9 were activated by NC treatment, which resulted in the apoptosis of ovarian cancer cells. The current study also examined the effect of NC on the expression levels of p53 in ovarian cancer cells and demonstrated the upregulation of p53 in a dose-dependent manner. These results indicated that NC-induced apoptosis of ovarian cancer cells may be a result of the imbalance between Bcl-2 and Bax expression levels, and the activation of caspase-3 and -9. Additionally, p53 was also demonstrated to be involved in NC-induced apoptosis of ovarian cancer cells.

Akt has been previously established as an important regulator of cell proliferation and survival (26). A previous study demonstrated that Akt mediated cell survival and apoptosis via its downstream targets, including Bad and caspase-9 (27). Another previous study indicated that Akt affected the regulation of Bax activity (28). The present study determined that the expression of p-Akt was decreased when cells were treated with NC. To determine whether the Akt signaling pathway was involved in NC-induced apoptosis of ovarian cancer cells and inhibited their proliferation, Akt phosphorylation was blocked by using the PI3K/Akt inhibitor, LY294002. It was demonstrated that the inhibition of Akt activity by LY294002 enhanced the apoptotic rate induced by NC, which was determined by western blot analysis and MTT assays. These results suggested that NC-induced apoptosis of ovarian cancer cells by inhibition of Akt phosphorylation and altering the expression levels of the Bcl-2 protein family members. The PI3K/Akt inhibitor (LY294002) enhancing the apoptotic rate induced by NC also suggested that Akt was located upstream of Bcl-2 and Bax.

To reduce the resistance to therapeutic agents, combination therapy is frequently used in cancer treatment (29). The anticancer agent DOX is highly effective for the treatment multiple types of cancer. However, there are problems with side effects, including acute and chronic cardiotoxicity, and neutropenia, which significantly limit its chemotherapeutic usage (30). Thus, it is important to develop combination therapies in order to decrease the side effects of chemotherapy agents. The present study determined the synergistic effect of NC and DOX in ovarian cancer cells. NC exerted a synergistic inhibitory effect on the viability of ovarian cancer cells and enhanced the anti-tumor effect when administered in conjunction with a low dose of DOX. This indicates that a combination of NC and DOX at certain concentrations may reduce its side effects. The precise mechanisms by which NC improves chemotherapeutic efficacy require further investigation.

In conclusion, to the best of our knowledge, the present study was the first to demonstrate that NC suppressed the proliferation of ovarian cancer cells and induced their apoptosis. Additionally, the effect of NC was demonstrated to be mediated by the Akt signaling pathway. NC exhibited a synergistic effect with DOX in ovarian cancer cells. Therefore, it was determined that NC is a promising agent for ovarian cancer therapy and additional in vivo studies are required to confirm its efficacy.

Acknowledgments

The present study was supported by the Natural Science Foundation of Shandong Province (grant no. ZR2014HP005).

References

1 

Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI

2 

Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI

3 

Cohen M, Pierredon S, Wuillemin C, Delie F and Petignat P: Acellular fraction of ovarian cancer ascites induce apoptosis by activating JNK and inducing BRCA1, Fas and FasL expression in ovarian cancer cells. Oncoscience. 1:262–271. 2014. View Article : Google Scholar

4 

Sun ZL, Tang YJ, Wu WG, Xing J, He YF, Xin DM, Yu YL, Yang Y and Han P: AZD1480 can inhibit the biological behavior of ovarian cancer SKOV3 cells in vitro. Asian Pac J Cancer Prev. 14:4823–4827. 2013. View Article : Google Scholar : PubMed/NCBI

5 

Holschneider CH and Berek JS: Ovarian cancer: Epidemiology, biology and prognostic factors. Semin Surg Oncol. 19:3–10. 2000. View Article : Google Scholar : PubMed/NCBI

6 

Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, et al: Rethinking ovarian cancer: Recommendations for improving outcomes. Nat Reviews Cancer. 11:719–725. 2011. View Article : Google Scholar : PubMed/NCBI

7 

Wang Z, Jiang W, Zhang Z, Qian M and Du B: Nitidine chloride inhibits LPS-induced inflammatory cytokines production via MAPK and NFkappab pathway in raw 264.7 cells. J Ethnopharmacol. 144:145–150. 2012. View Article : Google Scholar : PubMed/NCBI

8 

Del Poeta M, Chen SF, Von Hoff D, Dykstra CC, Wani MC, Manikumar G, Heitman J, Wall ME and Perfect JR: Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells. Antimicrob Agents Chemother. 43:2862–2868. 1999.PubMed/NCBI

9 

Fang Z, Tang Y, Jiao W, Xing Z, Guo Z, Wang W, Xu Z and Liu Z: Nitidine chloride induces apoptosis and inhibits tumor cell proliferation via suppressing ERK signaling pathway in renal cancer. Food Chem Toxicol. 66:210–216. 2014. View Article : Google Scholar : PubMed/NCBI

10 

Chen J, Wang J, Lin L, He L, Wu Y, Zhang L, Yi Z, Chen Y, Pang X and Liu M: Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer. Mol Cancer Ther. 11:277–287. 2012. View Article : Google Scholar

11 

Liao J, Xu T, Zheng JX, Lin JM, Cai QY, Yu DB and Peng J: Nitidine chloride inhibits hepatocellular carcinoma cell growth in vivo through the suppression of the JAK1/STAT3 signaling pathway. Int J Mol Med. 32:79–84. 2013.PubMed/NCBI

12 

Sun M, Zhang N, Wang X, Cai C, Cun J, Li Y, Lv S and Yang Q: Nitidine chloride induces apoptosis, cell cycle arrest and synergistic cytotoxicity with DOX in breast cancer cells. Tumour Biol. 35:10201–10212. 2014. View Article : Google Scholar : PubMed/NCBI

13 

Fang Z, Tang Y, Jiao W, Xing Z, Guo Z, Wang W, Shi B, Xu Z and Liu Z: Nitidine chloride inhibits renal cancer cell metastasis via suppressing AKT signaling pathway. Food Chem Toxicol. 60:246–251. 2013. View Article : Google Scholar : PubMed/NCBI

14 

Pan X, Han H, Wang L, Yang L, Li R, Li Z, Liu J, Zhao Q, Qian M, Liu M and Du B: Nitidine chloride inhibits breast cancer cells migration and invasion by suppressing c-Src/FAK associated signaling pathway. Cancer Lett. 313:181–191. 2011. View Article : Google Scholar : PubMed/NCBI

15 

Adams JM and Cory S: The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 26:1324–1337. 2007. View Article : Google Scholar : PubMed/NCBI

16 

Cai Q, Lin J, Wei L, Zhang L, Wang L, Zhan Y, Zeng J, Xu W, Shen A, Hong Z and Peng J: Hedyotis diffusa willd inhibits colorectal cancer growth in vivo via inhibition of STAT3 signaling pathway. Int J Mol Sci. 13:6117–6128. 2012. View Article : Google Scholar : PubMed/NCBI

17 

Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 3:768–780. 2003. View Article : Google Scholar : PubMed/NCBI

18 

Thomasset SC, Berry DP, Garcea G, Marczylo T, Steward WP and Gescher AJ: Dietary polyphenolic phytochemicals-promising cancer chemopreventive agents in humans? A review of their clinical properties. Int J Cancer. 120:451–458. 2007. View Article : Google Scholar

19 

Zhang Y, Zhuang Z, Meng Q, Jiao Y, Xu J and Fan S: Polydatin inhibits growth of lung cancer cells by inducing apoptosis and causing cell cycle arrest. Oncology lett. 7:295–301. 2014.

20 

Reed JC: Bcl-2: Prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am. 9:451–473. 1995.PubMed/NCBI

21 

Antonsson B: Bax and other pro-apoptotic Bcl-2 family 'killer-proteins' and their victim the mitochondrion. Cell Tissue Res. 306:347–361. 2001. View Article : Google Scholar : PubMed/NCBI

22 

Crompton M: Bax, Bid and the permeabilization of the mitochondrial outer membrane in apoptosis. Curr Opin Cell Biol. 12:414–419. 2000. View Article : Google Scholar : PubMed/NCBI

23 

Baffy G, Miyashita T, Williamson JR and Reed JC: Apoptosis induced by withdrawal of interleukin-3 (IL-3) from an IL-3-dependent hematopoietic cell line is associated with repartitioning of intracellular calcium and is blocked by enforced Bcl-2 oncoprotein production. J Biol Chem. 268:6511–6519. 1993.PubMed/NCBI

24 

Precht TA, Phelps RA, Linseman DA, Butts BD, Le SS, Laessig TA, Bouchard RJ and Heidenreich KA: The permeability transition pore triggers Bax translocation to mitochondria during neuronal apoptosis. Cell Death Differ. 12:255–265. 2005. View Article : Google Scholar : PubMed/NCBI

25 

Yu Q: Restoring p53-mediated apoptosis in cancer cells: New opportunities for cancer therapy. Drug Resist Updat. 9:19–25. 2006. View Article : Google Scholar : PubMed/NCBI

26 

Somanath PR, Vijai J, Kichina JV, Byzova T and Kandel ES: The role of PAK-1 in activation of MAP kinase cascade and oncogenic transformation by Akt. Oncogene. 28:2365–2369. 2009. View Article : Google Scholar : PubMed/NCBI

27 

Datta SR, Brunet A and Greenberg ME: Cellular survival: A play in three Akts. Genes Dev. 13:2905–2927. 1999. View Article : Google Scholar : PubMed/NCBI

28 

Gardai SJ, Hildeman DA, Frankel SK, Whitlock BB, Frasch SC, Borregaard N, Marrack P, Bratton DL and Henson PM: Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. J Biol Chem. 279:21085–21095. 2004. View Article : Google Scholar : PubMed/NCBI

29 

Khan KH, Blanco-Codesido M and Molife LR: Cancer therapeutics: Targeting the apoptotic pathway. Crit Rev Oncol Hematol. 90:200–219. 2014. View Article : Google Scholar : PubMed/NCBI

30 

Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ and Moens AL: DOX-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 52:1213–1225. 2012. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Ding F, Liu T, Yu N, Li S, Zhang X, Zheng G, Lv C, Mou K, Xu J, Li B, Li B, et al: Nitidine chloride inhibits proliferation, induces apoptosis via the Akt pathway and exhibits a synergistic effect with doxorubicin in ovarian cancer cells. Mol Med Rep 14: 2853-2859, 2016.
APA
Ding, F., Liu, T., Yu, N., Li, S., Zhang, X., Zheng, G. ... Song, H. (2016). Nitidine chloride inhibits proliferation, induces apoptosis via the Akt pathway and exhibits a synergistic effect with doxorubicin in ovarian cancer cells. Molecular Medicine Reports, 14, 2853-2859. https://doi.org/10.3892/mmr.2016.5577
MLA
Ding, F., Liu, T., Yu, N., Li, S., Zhang, X., Zheng, G., Lv, C., Mou, K., Xu, J., Li, B., Wang, S., Song, H."Nitidine chloride inhibits proliferation, induces apoptosis via the Akt pathway and exhibits a synergistic effect with doxorubicin in ovarian cancer cells". Molecular Medicine Reports 14.3 (2016): 2853-2859.
Chicago
Ding, F., Liu, T., Yu, N., Li, S., Zhang, X., Zheng, G., Lv, C., Mou, K., Xu, J., Li, B., Wang, S., Song, H."Nitidine chloride inhibits proliferation, induces apoptosis via the Akt pathway and exhibits a synergistic effect with doxorubicin in ovarian cancer cells". Molecular Medicine Reports 14, no. 3 (2016): 2853-2859. https://doi.org/10.3892/mmr.2016.5577
Copy and paste a formatted citation
x
Spandidos Publications style
Ding F, Liu T, Yu N, Li S, Zhang X, Zheng G, Lv C, Mou K, Xu J, Li B, Li B, et al: Nitidine chloride inhibits proliferation, induces apoptosis via the Akt pathway and exhibits a synergistic effect with doxorubicin in ovarian cancer cells. Mol Med Rep 14: 2853-2859, 2016.
APA
Ding, F., Liu, T., Yu, N., Li, S., Zhang, X., Zheng, G. ... Song, H. (2016). Nitidine chloride inhibits proliferation, induces apoptosis via the Akt pathway and exhibits a synergistic effect with doxorubicin in ovarian cancer cells. Molecular Medicine Reports, 14, 2853-2859. https://doi.org/10.3892/mmr.2016.5577
MLA
Ding, F., Liu, T., Yu, N., Li, S., Zhang, X., Zheng, G., Lv, C., Mou, K., Xu, J., Li, B., Wang, S., Song, H."Nitidine chloride inhibits proliferation, induces apoptosis via the Akt pathway and exhibits a synergistic effect with doxorubicin in ovarian cancer cells". Molecular Medicine Reports 14.3 (2016): 2853-2859.
Chicago
Ding, F., Liu, T., Yu, N., Li, S., Zhang, X., Zheng, G., Lv, C., Mou, K., Xu, J., Li, B., Wang, S., Song, H."Nitidine chloride inhibits proliferation, induces apoptosis via the Akt pathway and exhibits a synergistic effect with doxorubicin in ovarian cancer cells". Molecular Medicine Reports 14, no. 3 (2016): 2853-2859. https://doi.org/10.3892/mmr.2016.5577
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team